Figure 8. ANG II significantly increases Fos expression in regions downstream of the MnPO compared to controls and is blunted during CNO-induced inhibition in Gi DREADD-injected rats. A, Representative Fos staining in the SON (top row), PVN (middle row), and RVLM (bottom row) for each group tested. Scale bar, 100 µm. Supraoptic nucleus, SON; optic tract, ot: paraventricular nucleus, PVN; posterior magnocellular, PM; dorsal parvocellular, DP; medial parvocellular, MP; ventrolateral parvocellular, vlp; rostral ventral lateral medulla, RVLM. B, ANG II significantly increases Fos expression in the SFO, OVLT, PVN, and PVT but this increase was significantly attenuated during CNO-mediated inhibition in the MnPO, SON, LH, and RVLM. Subfornical organ, SFO; organum vasculosum of the lamina terminalis, OVLT; paraventricular thalamus, PVT; lateral hypothalamus, LH.C, ANG II significantly increases Fos staining in cardiovascular and neuroendocrine-regulating regions of the PVN, but is significantly attenuated by CNO-mediated inhibition in the PM and MP subregions; *p < 0.005 compared to VEH (CTRL + VEH + 0.9% SAL) and CNO (CTRL + CNO + 0.9% SAL) controls; #p < 0.001 Gi DREADD-injected rats compared to control virus-injected rats treated with CNO and ANG II (Gi DREADD + CNO + ANG II and CTRL + CNO + ANG II, respectively). Data are presented as mean and SEM.